Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. Guminski, A., Lim, A., Khushalani, N. I., Schmults, C. D., Hernandez-Aya, L., Modi, B., Dunn, L., Hughes, B., Chang, A. S., Hauschild, A., Migden, M., Gutzmer, R., Alam, M., Jankovic, V., Stankevich, E., Booth, J., Li, S., Lowy, I., Fury, M. G., Rischin, D. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.15_suppl.9526

View details for Web of Science ID 000487345806580